Dyadic International (Dyadic International) Days Sales Outstanding : 43.17 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Dyadic International Days Sales Outstanding?

Dyadic International's average Accounts Receivable for the three months ended in Dec. 2023 was $0.33 Mil. Dyadic International's Revenue for the three months ended in Dec. 2023 was $0.69 Mil. Hence, Dyadic International's Days Sales Outstanding for the three months ended in Dec. 2023 was 43.17.

The historical rank and industry rank for Dyadic International's Days Sales Outstanding or its related term are showing as below:

DYAI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.45 Med: 61.98 Max: 5774.58
Current: 37.14

During the past 13 years, Dyadic International's highest Days Sales Outstanding was 5774.58. The lowest was 13.45. And the median was 61.98.

DYAI's Days Sales Outstanding is ranked better than
79.53% of 889 companies
in the Biotechnology industry
Industry Median: 71.83 vs DYAI: 37.14

Dyadic International's Days Sales Outstanding increased from Dec. 2022 (8.95) to Dec. 2023 (43.17).

Dyadic International Days Sales Outstanding Historical Data

The historical data trend for Dyadic International's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International Days Sales Outstanding Chart

Dyadic International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

67.96

64.25

17.61

13.45

33.11

Dyadic International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															8.95	14.79	38.70	85.85	43.17

Competitive Comparison of Dyadic International's Days Sales Outstanding

For the Biotechnology subindustry, Dyadic International's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dyadic International's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Dyadic International's Days Sales Outstanding falls into.

Dyadic International Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Dyadic International's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.115	+	0.411)	/	2 )	/	2.899	*	365
=	0.263					/	2.899	*	365
=	33.11

Dyadic International's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.239	+	0.411)	/	2 )	/	0.687	*	365 / 4
=	0.325					/	0.687	*	365 / 4
=	43.17

Dyadic International (NAS:DYAI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Dyadic International Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Dyadic International's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Dyadic International (Dyadic International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL, USA, 33477

Website

https://www.dyadic.com

Dyadic International Inc is a global biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Executives

Ronen Tchelet	officer: VP of Research and Bus. Dvlpmt	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb	director, 10 percent owner, officer: President, CEO & Chairman	C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton	officer: Chief Business Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996	10 percent owner	C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones	officer: Managing Dir of BD & Licensing	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst	director	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland	director	C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson	officer: Chief Financial Officer	140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok	director	KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose	director	4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye	director	C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson	10 percent owner	1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda	10 percent owner	410 S LUCERNE BLVD, LOS ANGELES CA 90020